• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu
VIEW ALL RESEARCH-GROUP

Molecular signaling
Viñals’s lab

DESCRIPTION

Our research is focused on the study of the implication of intracellular signaling cascades driving to pathological situations in cancer and vascular diseases.

The molecular signaling cascades that take place inside the cells are essential to respond to changes in their environment or to alter their homeostasis, for example, at the level of cell proliferation, movement, growth or metabolism. Understanding how these mechanisms of signal transduction work can explain how biological processes are controlled in a normal physiological context, but also, the alterations that take place in many pathologies. Our group investigates this in two pathological contexts: The first is ovarian epithelial cancer, where we study the pathways involved in metastasis and the mechanisms of resistance to therapies. A second context is a rare vascular disease, HHTs, in which, in collaboration with the group led by Toni Riera (Hospital de Bellvitge), we study which signaling pathways are altered in patients with mutations that cause this disease, and how treat them with new drugs.

Group members

Francesc Viñals

Group leaders

Group Leader

Agnès Figueras

Researchers

Núria Gendrau Sanclemente

PhD student

Ferran Medina Jover

PhD student

José Luís Rocamora

PhD student

Tianyu Dai

PhD student

Publications

Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia

23 de April de 2021/in Viñals's lab/by miguel

Eur J Intern Med. 2021 Jun;88:89-95. doi: 10.1016/j.ejim.2021.03.039. Epub 2021 Apr 20. ABSTRACT BACKGROUND: Adrenomedullin (AM) is a vasoactive peptide mostly secreted by endothelial cells with an important role in preserving endothelial integrity. The relationship between AM and hereditary hemorrhagic telangiectasia (HHT) is unknown. We aimed to compare the serum levels and tissue expression of […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-04-23 10:00:002021-04-23 10:00:00Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia

PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner

8 de January de 2021/in Viñals's lab/by miguel

Cancer Metab. 2021 Jan 7;9(1):1. doi: 10.1186/s40170-020-00236-3. ABSTRACT BACKGROUND: Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M; PCK2) is expressed in all cancer types examined and in neuroprogenitor cells. The gene is upregulated by amino acid limitation and ER-stress in an ATF4-dependent manner, and its activity modulates the PEP/Ca2+ signaling axis, providing clear arguments for a functional relationship with […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-01-08 11:00:002021-01-08 11:00:00PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

2 de December de 2020/in Viñals's lab/by miguel

Clin Cancer Res. 2021 Mar 1;27(5):1491-1504. doi: 10.1158/1078-0432.CCR-20-0232. Epub 2020 Dec 1. ABSTRACT PURPOSE: Recurrent and/or metastatic unresectable cutaneous squamous cell carcinomas (cSCCs) are treated with chemotherapy or radiotherapy, but have poor clinical responses. A limited response (up to 45% of cases) to EGFR-targeted therapies was observed in clinical trials with patients with advanced and […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2020-12-02 11:00:002020-12-02 11:00:00FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

SGK1 is a signalling hub that controls protein synthesis and proliferation in endothelial cells

9 de August de 2020/in Viñals's lab/by miguel

FEBS Lett. 2020 Oct;594(19):3200-3215. doi: 10.1002/1873-3468.13901. Epub 2020 Aug 20. ABSTRACT BMP9 is a cytokine involved in the maturation phase of the angiogenic process that signals through its serine/threonine receptor ALK1 and its coreceptor endoglin. In this paper, we explain how BMP9 directs the regulation of endothelial cell proliferation blockage while in turn stimulating protein […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2020-08-09 10:00:002020-08-09 10:00:00SGK1 is a signalling hub that controls protein synthesis and proliferation in endothelial cells

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

14 de May de 2020/in Viñals's lab/by miguel

EMBO Mol Med. 2020 Jun 8;12(6):e11217. doi: 10.15252/emmm.201911217. Epub 2020 May 13. ABSTRACT Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2020-05-14 10:00:002020-05-14 10:00:00Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Page 5 of 23«‹34567›»

Research Projects

– Ref: PID2020-117815RB-I00 Title: El perfil metabólico como una oportunidad terapéutica en el cáncer epitelial de ovario. implicaciones en metástasis y resistencia a los tratamientos. DGICYT, MINECO. 2021-2024. 217.800 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

– Ref: SAF2017-85869-R Title: Mecanismos de señalización y control metabólico implicados en la diseminación y quimioresistencia en cáncer epitelial de ovario. DGICYT, MINECO. 2018-2020. 181.500 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

Collaborations

Peter B. Vermeulen, University of Antwerp and GZA Hospitals, Belgium
Artur Mezheyeuski, VHIO, Barcelona
Pnina Brodt, Mc Gill University, Montreal, Canada
and Liver Metastases Research Network members

Viñals's lab
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Casanovas’ LabCasanovas's Lab
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}